Axa S.A. Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

AXA S.A. grew its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 57.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,195 shares of the company's stock after buying an additional 61,040 shares during the period. AXA S.A.'s holdings in Novo Nordisk A/S were worth $14,468,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. Center for Financial Planning Inc. lifted its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL boosted its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $39,000. Finally, Albion Financial Group UT raised its stake in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NVO. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Trading Up 1.8 %

NYSE:NVO traded up $1.20 during trading hours on Wednesday, reaching $67.49. 14,140,917 shares of the stock were exchanged, compared to its average volume of 6,286,842. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $70.60 and a two-hundred day moving average of $87.08. The company has a market capitalization of $302.88 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.